{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:28:14Z","timestamp":1790674094943,"version":"4.1.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T00:00:00Z","timestamp":1572480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG17009"],"award-info":[{"award-number":["IG17009"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG15216"],"award-info":[{"award-number":["IG15216"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG19865"],"award-info":[{"award-number":["IG19865"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009880","name":"Regione Lazio","doi-asserted-by":"publisher","award":["85-2017-13750"],"award-info":[{"award-number":["85-2017-13750"]}],"id":[{"id":"10.13039\/501100009880","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Originally described as interpatient variability, tumour heterogeneity has now been demonstrated to occur intrapatiently, within the same lesion, or in different lesions of the same patient. Tumour heterogeneity involves both genetic and epigenetic changes. Intrapatient heterogeneity is responsible for generating subpopulations of cancer cells which undergo clonal evolution with time. Tumour heterogeneity develops also as a consequence of the selective pressure imposed by the immune system. It has been demonstrated that tumour heterogeneity and different spatiotemporal interactions between all the cellular compontents within the tumour microenvironment lead to cancer adaptation and to therapeutic pressure. In this context, the recent advent of single cell analysis approaches which are able to better study tumour heterogeneity from the genomic, transcriptomic and proteomic standpoint represent a major technological breakthrough. In this review, using metastatic melanoma as a prototypical example, we will focus on applying single cell analyses to the study of clonal trajectories which guide the evolution of drug resistance to targeted therapy.<\/jats:p>","DOI":"10.1038\/s41419-019-2048-5","type":"journal-article","created":{"date-parts":[[2019,10,31]],"date-time":"2019-10-31T15:12:59Z","timestamp":1572534779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Single cell analysis to dissect molecular heterogeneity and disease evolution in metastatic melanoma"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9245-0126","authenticated-orcid":false,"given":"Luigi","family":"Fattore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciro Francesco","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Liguoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-8605","authenticated-orcid":false,"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,31]]},"reference":[{"key":"2048_CR1","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2017","unstructured":"Dagogo-Jack, I. & Shaw, A. T. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol. 15, 81 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2048_CR2","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein, B. et al. Cancer Genome Landscapes. Science 339, 1546 (2013).","journal-title":"Science"},{"key":"2048_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/nm.3841","volume":"21","author":"HC Bhang","year":"2015","unstructured":"Bhang, H. C. et al. Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nat. Med. 21, 440 (2015).","journal-title":"Nat. Med."},{"key":"2048_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-14-1429","volume":"21","author":"M Jamal-Hanjani","year":"2015","unstructured":"Jamal-Hanjani, M., Quezada, S. A., Larkin, J. & Swanton, C. Translational implications of tumor heterogeneity. Clin. Cancer Res. 21, 1258 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2048_CR5","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","volume":"175","author":"M Angelova","year":"2018","unstructured":"Angelova, M. et al. Evolution of metastases in space and time under immune selection. Cell 175, 751\u2013765.e16 (2018).","journal-title":"Cell"},{"key":"2048_CR6","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","volume":"10","author":"TM Grzywa","year":"2017","unstructured":"Grzywa, T. M., Paskal, W. & W\u00c5\u201aodarski, P. K. Intratumor and intertumor heterogeneity in melanoma. Transl. Oncol. 10, 956\u2013975 (2017).","journal-title":"Transl. Oncol."},{"key":"2048_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2013.07.011","volume":"39","author":"J van\u00c2 den\u00c2 Boorn","year":"2013","unstructured":"van\u00c2 den\u00c2 Boorn, J. & Hartmann, G. Turning tumors into vaccines: co-opting the innate immune system. Immunity 39, 27\u201337 (2013).","journal-title":"Immunity"},{"key":"2048_CR8","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.molonc.2012.01.002","volume":"6","author":"TF Gajewski","year":"2012","unstructured":"Gajewski, T. F. Cancer immunotherapy. Mol. Oncol. 6, 242\u2013250 (2012).","journal-title":"Mol. Oncol."},{"key":"2048_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.cell.2014.02.010","volume":"157","author":"J Junker","year":"2014","unstructured":"Junker, J. & van\u00c2 Oudenaarden, A. Every cell is special: genome-wide studies add a new dimension to single-cell biology. Cell 157, 8\u201311 (2014).","journal-title":"Cell"},{"key":"2048_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.stem.2014.10.015","volume":"15","author":"M Etzrodt","year":"2014","unstructured":"Etzrodt, M., Endele, M. & Schroeder, T. Quantitative single-cell approaches to stem cell research. Cell Stem Cell 15, 546\u2013558 (2014).","journal-title":"Cell Stem Cell"},{"key":"2048_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-018-0071-8","volume":"50","author":"B Hwang","year":"2018","unstructured":"Hwang, B., Lee, J. H. & Bang, D. Single-cell RNA sequencing technologies and bioinformatics pipelines. Exp. Mol. Med. 50, 96 (2018).","journal-title":"Exp. Mol. Med."},{"key":"2048_CR12","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41576-019-0093-7","volume":"20","author":"T Stuart","year":"2019","unstructured":"Stuart, T. & Satija, R. Integrative single-cell analysis. Nat. Rev. Genet. 20, 257\u2013272 (2019).","journal-title":"Nat. Rev. Genet."},{"key":"2048_CR13","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1016\/j.cell.2019.05.031","volume":"177","author":"T Stuart","year":"2019","unstructured":"Stuart, T. et al. Comprehensive integration of single-cell data. Cell 177, 1888\u20131902.e21 (2019).","journal-title":"Cell"},{"key":"2048_CR14","doi-asserted-by":"crossref","unstructured":"Zhang, Q. et al. Integrated multiomic analysis reveals comprehensive tumour heterogeneity and novel immunophenotypic classification in hepatocellular carcinomas. Gut, gutjnl-2019-318912 (2019).","DOI":"10.1136\/gutjnl-2019-318912"},{"key":"2048_CR15","doi-asserted-by":"publisher","first-page":"22262","DOI":"10.18632\/oncotarget.14763","volume":"8","author":"L Fattore","year":"2017","unstructured":"Fattore, L. et al. MicroRNAs in melanoma development and resistance to target therapy. Oncotarget 8, 22262\u201322278 (2017).","journal-title":"Oncotarget"},{"key":"2048_CR16","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"R Akbani","year":"2015","unstructured":"Akbani, R. et al. Genomic classification of cutaneous melanoma. Cell 161, 1681\u20131696 (2015).","journal-title":"Cell"},{"key":"2048_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196 (2016).","journal-title":"Science"},{"key":"2048_CR18","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s13046-018-0989-7","volume":"37","author":"ME Pisanu","year":"2018","unstructured":"Pisanu, M. E. et al. Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma. J. Exp. Clin. cancer Res. 37, 318\u2013318 (2018).","journal-title":"J. Exp. Clin. cancer Res."},{"key":"2048_CR19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1535-7163.MCT-16-0535","volume":"16","author":"A Ahn","year":"2017","unstructured":"Ahn, A., Chatterjee, A. & Eccles, M. R. The slow cycling phenotype: a growing problem for treatment resistance in melanoma. Mol. Cancer Ther. 16, 1002 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"2048_CR20","doi-asserted-by":"publisher","first-page":"846","DOI":"10.18632\/oncotarget.13666","volume":"8","author":"T Gerber","year":"2017","unstructured":"Gerber, T. et al. Mapping heterogeneity in patient-derived melanoma cultures by single-cell RNA-seq. Oncotarget 8, 846\u2013862 (2017).","journal-title":"Oncotarget"},{"key":"2048_CR21","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel, A. P. et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344, 1396 (2014).","journal-title":"Science"},{"key":"2048_CR22","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/s41388-018-0141-3","volume":"37","author":"R Mancini","year":"2018","unstructured":"Mancini, R. et al. Metabolic features of cancer stem cells: the emerging role of lipid metabolism. Oncogene 37, 2367\u20132378 (2018).","journal-title":"Oncogene"},{"key":"2048_CR23","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/biology7020023","volume":"7","author":"H Loeffler-Wirth","year":"2018","unstructured":"Loeffler-Wirth, H., Binder, H., Willscher, E., Gerber, T. & Kunz, M. Pseudotime dynamics in melanoma single-cell transcriptomes reveals different mechanisms of tumor progression. Biology 7, 23 (2018).","journal-title":"Biology"},{"key":"2048_CR24","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.fct.2014.11.025","volume":"76","author":"P Costanzo","year":"2015","unstructured":"Costanzo, P., Santini, A., Fattore, L., Novellino, E. & Ritieni, A. Toxicity of aflatoxin B1 towards the vitamin D receptor (VDR). Food Chem. Toxicol. 76, 77\u201379 (2015).","journal-title":"Food Chem. Toxicol."},{"key":"2048_CR25","doi-asserted-by":"publisher","first-page":"6136","DOI":"10.1038\/s41388-018-0385-y","volume":"37","author":"M Kunz","year":"2018","unstructured":"Kunz, M. et al. RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas. Oncogene 37, 6136\u20136151 (2018).","journal-title":"Oncogene"},{"key":"2048_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35\u201344 (2016).","journal-title":"Cell"},{"key":"2048_CR27","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41568-019-0154-4","volume":"19","author":"I Arozarena","year":"2019","unstructured":"Arozarena, I. & Wellbrock, C. Phenotype plasticity as enabler of\u00c2 melanoma progression and therapy\u00c2 resistance. Nat. Rev. Cancer 19, 377\u2013391 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"2048_CR28","doi-asserted-by":"crossref","unstructured":"Bai, X., Fisher, D. E. & Flaherty, K. T. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFN\u00ce\u00b3 pathways. Nat. Rev. Clin. Oncol. 16, 549\u2013562 (2019).","DOI":"10.1038\/s41571-019-0204-6"},{"key":"2048_CR29","doi-asserted-by":"publisher","first-page":"7097","DOI":"10.1158\/1078-0432.CCR-17-0010","volume":"23","author":"M Ennen","year":"2017","unstructured":"Ennen, M. et al. MITF-high and MITF-low cells and a novel subpopulation expressing genes of both cell states contribute to intra-and intertumoral heterogeneity of primary melanoma. Clin. Cancer Res. 23, 7097 (2017).","journal-title":"Clin. Cancer Res."},{"key":"2048_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.bbcan.2019.02.002","volume":"1871","author":"I Kozar","year":"2019","unstructured":"Kozar, I., Margue, C., Rothengatter, S., Haan, C. & Kreis, S. Many ways to resistance: How melanoma cells evade targeted therapies. Biochimica et. Biophysica Acta (BBA) - Rev. Cancer 1871, 313\u2013322 (2019).","journal-title":"Biochimica et. Biophysica Acta (BBA) - Rev. Cancer"},{"key":"2048_CR31","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1016\/j.celrep.2018.10.047","volume":"25","author":"MP Kumar","year":"2018","unstructured":"Kumar, M. P. et al. Analysis of single-cell RNA-seq identifies cell-cell communication associated with tumor characteristics. Cell Rep. 25, 1458\u20131468.e4 (2018).","journal-title":"Cell Rep."},{"key":"2048_CR32","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke, J. J., Flaherty, K. T., Ribas, A. & Long, G. V. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat. Rev. Clin. Oncol. 14, 463 (2017).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"2048_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cytogfr.2017.05.003","volume":"36","author":"L Fattore","year":"2017","unstructured":"Fattore, L., Sacconi, A., Mancini, R. & Ciliberto, G. MicroRNA-driven deregulation of cytokine expression helps development of drug resistance in metastatic melanoma. Cytokine Growth Factor Rev. 36, 39\u201348 (2017).","journal-title":"Cytokine Growth Factor Rev."},{"key":"2048_CR34","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","volume":"27","author":"G Moriceau","year":"2015","unstructured":"Moriceau, G. et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 27, 240\u2013256 (2015).","journal-title":"Cancer Cell"},{"key":"2048_CR35","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"2048_CR36","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1158\/2159-8290.CD-13-0642","volume":"4","author":"H Shi","year":"2014","unstructured":"Shi, H. et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 4, 80\u201393 (2014).","journal-title":"Cancer Discov."},{"key":"2048_CR37","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.cell.2015.07.061","volume":"162","author":"W Hugo","year":"2015","unstructured":"Hugo, W. et al. Non-genomic and immune evolution of melanoma acquiring MAPKi resistance. Cell 162, 1271\u20131285 (2015).","journal-title":"Cell"},{"key":"2048_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/1479-5876-11-180","volume":"11","author":"L Fattore","year":"2013","unstructured":"Fattore, L. et al. Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF\/MEK inhibition and is abrogated by anti-ErbB3 antibodies. J. Transl. Med. 11, 180\u2013180 (2013).","journal-title":"J. Transl. Med."},{"key":"2048_CR39","doi-asserted-by":"publisher","first-page":"24823","DOI":"10.18632\/oncotarget.4485","volume":"6","author":"L Fattore","year":"2015","unstructured":"Fattore, L. et al. Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF\/MEK inhibitors in melanoma. Oncotarget 6, 24823\u201324841 (2015).","journal-title":"Oncotarget"},{"key":"2048_CR40","doi-asserted-by":"publisher","first-page":"E5005","DOI":"10.1073\/pnas.1607753113","volume":"113","author":"L Fattore","year":"2016","unstructured":"Fattore, L. et al. miR-579-3p controls melanoma progression and resistance to target therapy. Proc. Natl Acad. Sci. USA 113, E5005\u2013E5013 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2048_CR41","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1101\/gr.234062.117","volume":"28","author":"Y Ho","year":"2018","unstructured":"Ho, Y. et al. Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations. Genome Res. 28, 1353\u20131363 (2018).","journal-title":"Genome Res."},{"key":"2048_CR42","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/nature22794","volume":"546","author":"SM Shaffer","year":"2017","unstructured":"Shaffer, S. M. et al. Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance. Nature 546, 431 (2017).","journal-title":"Nature"},{"key":"2048_CR43","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.cell.2018.06.025","volume":"174","author":"F Rambow","year":"2018","unstructured":"Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843\u2013855.e19 (2018).","journal-title":"Cell"},{"key":"2048_CR44","doi-asserted-by":"publisher","first-page":"13679","DOI":"10.1073\/pnas.1712064115","volume":"114","author":"Y Su","year":"2017","unstructured":"Su, Y. et al. Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance. Proc. Natl Acad. Sci. USA 114, 13679\u201313684 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2048_CR45","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.molcel.2019.04.021","volume":"74","author":"X Lun","year":"2019","unstructured":"Lun, X. et al. Analysis of the human kinome and phosphatome by mass cytometry reveals overexpression-induced effects on cancer-related signaling. Mol. Cell 74, 1086\u20131102.e5 (2019).","journal-title":"Mol. Cell"},{"key":"2048_CR46","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/nm.4466","volume":"24","author":"C Krieg","year":"2018","unstructured":"Krieg, C. et al. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat. Med. 24, 144 (2018).","journal-title":"Nat. Med."},{"key":"2048_CR47","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.cell.2017.06.016","volume":"170","author":"CJ Nirschl","year":"2017","unstructured":"Nirschl, C. J. et al. IFN\u00ce\u00b3-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell 170, 127\u2013141.e15 (2017).","journal-title":"Cell"},{"key":"2048_CR48","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.cell.2018.09.006","volume":"175","author":"L Jerby-Arnon","year":"2018","unstructured":"Jerby-Arnon, L. et al. A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade. Cell 175, 984\u2013997.e24 (2018).","journal-title":"Cell"},{"key":"2048_CR49","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998\u20131013.e20 (2018).","journal-title":"Cell"},{"key":"2048_CR50","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.immuni.2010.08.002","volume":"33","author":"X Zhou","year":"2010","unstructured":"Zhou, X. et al. Differentiation and persistence of memory CD8+ T cells depend on T cell factor 1. Immunity 33, 229\u2013240 (2010).","journal-title":"Immunity"},{"key":"2048_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ccell.2019.01.003","volume":"35","author":"TN Gide","year":"2019","unstructured":"Gide, T. N. et al. Distinct immune cell populations define response to anti-PD-1 monotherapy and anti-PD-1\/anti-CTLA-4 combined therapy. Cancer Cell 35, 238\u2013255.e6 (2019).","journal-title":"Cancer Cell"},{"key":"2048_CR52","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/ni1268","volume":"6","author":"AM Intlekofer","year":"2005","unstructured":"Intlekofer, A. M. et al. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat. Immunol. 6, 1236\u20131244 (2005).","journal-title":"Nat. Immunol."},{"key":"2048_CR53","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1158\/2159-8290.CD-17-0343","volume":"7","author":"N Amirouchene-Angelozzi","year":"2017","unstructured":"Amirouchene-Angelozzi, N., Swanton, C. & Bardelli, A. Tumor evolution as a therapeutic target. Cancer Disco. 7, 805 (2017).","journal-title":"Cancer Disco."},{"issue":"1","key":"2048_CR54","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1479-5876-12-54","volume":"12","author":"Giuseppe Roscilli","year":"2014","unstructured":"Roscilli, G. et al. Circulating MMP11 and specific antibody immune response in breast and prostate cancer patients. J. Transl. Med. 12, 54-5876-12-54 (2014).","journal-title":"Journal of Translational Medicine"},{"key":"2048_CR55","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1158\/1535-7163.MCT-18-0174","volume":"17","author":"HM Naml\u00c3\u00b8s","year":"2018","unstructured":"Naml\u00c3\u00b8s, H. M. et al. Noninvasive detection of ctDNA reveals intratumor heterogeneity and is associated with tumor burden in gastrointestinal stromal tumor. Mol. Cancer Ther. 17, 2473 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"2048_CR56","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","volume":"404","author":"L Calapre","year":"2017","unstructured":"Calapre, L., Warburton, L., Millward, M., Ziman, M. & Gray, E. S. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Lett. 404, 62\u201369 (2017).","journal-title":"Cancer Lett."},{"key":"2048_CR57","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/nm.3870","volume":"21","author":"G Siravegna","year":"2015","unstructured":"Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795\u2013801 (2015).","journal-title":"Nat. Med."},{"key":"2048_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/14728222.2019.1554057","volume":"23","author":"L Fattore","year":"2019","unstructured":"Fattore, L., Mancini, R., Ascierto, P. A. & Ciliberto, G. The potential of BRAF-associated non-coding RNA as a therapeutic target in melanoma. Expert Opin. Therapeutic Targets 23, 53\u201368 (2019).","journal-title":"Expert Opin. Therapeutic Targets"},{"key":"2048_CR59","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s41418-018-0205-5","volume":"26","author":"L Fattore","year":"2019","unstructured":"Fattore, L. et al. Reprogramming miRNAs global expression orchestrates development of drug resistance in BRAF mutated melanoma. Cell Death Differ. 26, 1267\u20131282 (2019).","journal-title":"Cell Death Differ."},{"key":"2048_CR60","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3389\/fonc.2019.00526","volume":"9","author":"S Giglio","year":"2019","unstructured":"Giglio, S. et al. miRNAs as candidate biomarker for the accurate detection of atypical endometrial hyperplasia\/endometrial intraepithelial neoplasia. Front. Oncol. 9, 526\u2013526 (2019).","journal-title":"Front. Oncol."},{"key":"2048_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/biom8020021","volume":"8","author":"SL Mumford","year":"2018","unstructured":"Mumford, S. L. et al. Circulating microRNA biomarkers in melanoma: tools and challenges in personalised medicine. Biomolecules 8, 21 (2018).","journal-title":"Biomolecules"},{"key":"2048_CR62","doi-asserted-by":"publisher","first-page":"E4203","DOI":"10.1073\/pnas.1620562114","volume":"114","author":"M Acunzo","year":"2017","unstructured":"Acunzo, M. et al. Selective targeting of point-mutated KRAS through artificial microRNAs. Proc. Natl Acad. Sci. USA 114, E4203\u2013E4212 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2048_CR63","doi-asserted-by":"crossref","unstructured":"Thiele, J. A., Pitule, P., Hicks, J. & Kuhn, P. in Tumor Profiling: Methods and Protocols (ed Murray, S. S.) 243\u2013264 (Springer New York, New York, NY, 2019).","DOI":"10.1007\/978-1-4939-9004-7_17"},{"key":"2048_CR64","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1038\/nbt.2282","volume":"30","author":"D Ramsk\u00c3\u00b6ld","year":"2012","unstructured":"Ramsk\u00c3\u00b6ld, D. et al. Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. Nat. Biotechnol. 30, 777\u2013782 (2012).","journal-title":"Nat. Biotechnol."},{"key":"2048_CR65","first-page":"59","volume-title":"Diagnostics","author":"K Leone","year":"2018","unstructured":"Leone, K., Poggiana, C. & Zamarchi, R. The interplay between circulating tumor cells and the immune system: from immune escape to cancer immunotherapy. Diagnostics 8, 59 (2018)."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2048-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2048-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T17:46:49Z","timestamp":1671212809000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-019-2048-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,31]]},"references-count":65,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2019,11]]}},"alternative-id":["2048"],"URL":"https:\/\/doi.org\/10.1038\/s41419-019-2048-5","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,31]]},"assertion":[{"value":"10 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"827"}}